Disorders of fat partitioning in treated HIV-infection

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 25, Issue 3, 2011, Pages 415-427

  Martínez, Esteban ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

lipoatrophy; lipodystrophy; lipohypertrophy; management; pathogenesis; prevention; risk factors

Indexed keywords

RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; THYMIDINE DERIVATIVE; ZIDOVUDINE;

ARTICLE; BODY FAT; DIET; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXERCISE; FACE DEFORMITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAABDOMINAL FAT; LIPOATROPHY; LIPODYSTROPHY; LIPOHYPERTROPHY; LIPOSUCTION; PATHOGENESIS; SUBCUTANEOUS FAT; WEIGHT GAIN;

EID: 79958282800     PISSN: 1521690X     EISSN: 15321908     Source Type: Journal    
DOI: 10.1016/j.beem.2010.10.019     Document Type: Review

References (109)

1. A. Carr, K. Samaras, and S. Burton A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors AIDS 12 1998 F51 F58
2. F.J. Palella Jr., K.M. Delaney, and A.C. Moorman Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection The New England Journal of Medicine 338 1998 853 860 (Pubitemid 28135961)
3. K. Brinkman, J.A. Smeitink, and J.A. Romijn Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy Lancet 354 1999 1112 1115 (Pubitemid 29452832)
4. E. Martinez, A. Mocroft, and M.A. Garcia-Viejo Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study Lancet 357 2001 592 598 (Pubitemid 32179612)
5. K.A. Lichtenstein, K.M. Delaney, and C. Armon Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients Journal of Acquired Immune Deficiency Syndromes 32 2003 48 56 (Pubitemid 36091484)
6. E. Cabrero, L. Griffa, and A. Burgos Prevalence and impact of body physical changes in HIV patients treated with highly active antiretroviral therapy: results from a study on patient and physician perceptions AIDS Patient Care STDs 24 2010 5 13
7. D. Podzamczer, E. Ferrer, and E. Martinez How much fat loss is needed for lipoatrophy to become clinically evident? AIDS Research and Human Retroviruses 25 2009 563 567
8. T. Saint-Marc, M. Partisani, and I. Poizot-Martin Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study AIDS 14 2000 37 49 (Pubitemid 30072076)
9. C.T. Montague, and S. O'Rahilly The perils of portliness: causes and consequences of visceral adiposity Diabetes 49 2000 883 888 (Pubitemid 30349408)
10. P. Bacchetti, B. Gripshover, and C. Grunfeld Fat distribution in men with HIV infection Journal of Acquired Immune Deficiency Syndromes 40 2005 121 131 (Pubitemid 41395709)
11. A. Carr, J. Miller, and M. Law A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lypodystrophy syndrome AIDS 14 2000 F25 F32
12. D. Periard, A. Telenti, and P. Sudre Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study Circulation 100 1999 700 705 (Pubitemid 29383638)
13. P.W. Mallon, J. Miller, and D.A. Cooper Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy AIDS 17 2003 971 979 (Pubitemid 36549708)
14. M. Galli, A. Cozzi-Lepri, and A.L. Ridolfo Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa Study Archives of Internal Medicine 162 2002 2621 2628 (Pubitemid 35453502)
15. S. Mauss, M. Corzillius, and E. Wolf Risk factors for the HIV-associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment HIV Medicine 3 2002 49 55 (Pubitemid 34189596)
16. A. Nguyen, A. Calmy, and V. Schiffer Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006 HIV Medicine 9 2008 142 150 (Pubitemid 351283131)
17. D. Podzamczer, E. Ferrer, and P. Sanchez Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study Journal of Acquired Immune Deficiency Syndromes 44 2007 139 147 (Pubitemid 46292215)
18. Valantin MA, Flandre P, Kohtla S. et al. Fat tissue distribution changes in HIV-infected patients with viral suppression treated with CDRV/r monotherapy vs 2 NRTI + DRV/r in the MONOI-ANRS 136 randomized trial: results at 48 weeks. 17th Conference on retrovirus and Opportunistic Infections Feb 16-19 2010 San Francisco; 2010 Abstract 721.
19. A. Carr, K. Samaras, and D.J. Chisholm Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance Lancet 351 1998 1881 1883 (Pubitemid 28279721)
20. R.H. Haubrich, S.A. Riddler, and A.G. DiRienzo Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment AIDS 23 2009 1109 1118
21. McComsey G, Rightmire R, Wirtz V. et al. Body composition changes in ARV-naive subjects treated with atazanavir or atazanavir/ritonavir-based once-daily HAART: 96-week CT and DEXA data. 11th European AIDS Conference; Madrid, Spain; 24-27 October 2007; 2007 Abstract P9.3/04.
22. Moyle G, Hu W, Yang R. et al. Body composition changes in treatment-naïve patients treated with boosted protease inhibitors plus tenofovir/emtricitabine. Results from the Castle trial from 96 weeks. 12th European AIDS Conference November 11-14, 2009 Cologne, Germany 2009; Abstract LBPS11/6.
23. J.E. Gallant, S. Staszewski, and A.L. Pozniak Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial JAMA: the Journal of the American Medical Association 292 2004 191 201 (Pubitemid 38917996)
24. J.E. Gallant, E. DeJesus, and J.R. Arribas Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV The New England Journal of Medicine 354 2006 251 260 (Pubitemid 43113030)
25. DeJesus E, Cohen C, Lennox J. et al. Metabolic profiles and body composition changes in treatment-naive HIV-infected patients treated with raltegravir 400 mg twice-daily vs efavirenz 600 mg each bedtime combination therapy: 96-week follow-up. 17th Conference on Retrovirus and Opportunistic Infections Feb 16-19, 2010 San Francisco 2010; Abstract 720.
26. Cooper DA, Cordery DV, Reiss P. et al. The effects of enfuvirtide on body composition and metabolic parameters over 48 weeks in the TORO body imaging substudy. HIV Med (in press).
27. K.D. Miller, E. Jones, and J.A. Yanovski Visceral abdominal-fat accumulation associated with use of indinavir Lancet 351 1998 871 875 (Pubitemid 28121176)
28. F. Jover, J.M. Cuadrado, and P. Roig Efavirenz-associated gynecomastia: report of five cases and review of the literature The Breast Journal 10 2004 244 246 (Pubitemid 38715743)
29. A. Biglia, J.L. Blanco, and E. Martínez Gynecomastia among HIV-infected patients is associated with hypogonadism: a case-control study Clinical Infectious Diseases 39 2004 1514 1519 (Pubitemid 39518217)
30. M.L. Gougeon, L. Penicaud, and B. Fromenty Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations Antiviral Therapy 9 2004 161 177 (Pubitemid 38560209)
31. M. Sievers, U.A. Walker, and K. Sevastianova Gene expression and immunohistochemistry in adipose tissue of HIV type 1-infected patients with nucleoside analogue reverse-transcriptase inhibitor-associated lipoatrophy The Journal of Infectious Diseases 200 2009 252 262
32. M.J. Kim, C. Jardel, and C. Barthelemy Mitochondrial DNA content, an inaccurate biomarker of mitochondrial alteration in human immunodeficiency virus-related lipodystrophy Antimicrobial Agents and Chemotherapy 52 2008 1670 1676 (Pubitemid 351614659)
33. D.S. Zhong, X.H. Lu, and B.S. Conklin HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells Arteriosclerosis, Thrombosis, and Vascular Biology 22 2002 1560 1566
34. M. Caron-Debarle, C. Lagathu, and F. Boccara HIV-associated lipodystrophy: from fat injury to premature aging Trends in Molecular Medicine 16 2010 218 229
35. G. Lenaz, A. Baracca, and V. Carelli Bioenergetics of mitochondrial diseases associated with mtDNA mutations Biochimica et Biophysica Acta 1658 2004 89 94 (Pubitemid 39013238)
36. P.V. Nerurkar, C.M. Shikuma, and V.R. Nerurkar Sterol regulatory element-binding proteins and reactive oxygen species: potential role in highly-active antiretroviral therapy (HAART)-associated lipodystrophy Clinical Biochemistry 34 2001 519 529 (Pubitemid 34014844)
37. C.S. Pace, A.M. Martin, and E.L. Hammond Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients Antiviral Therapy 8 2003 323 331 (Pubitemid 37101636)
38. A. Carriere, Y. Fernandez, and M. Rigoulet Inhibition of preadipocyte proliferation by mitochondrial reactive oxygen species FEBS Letters 550 2003 163 167 (Pubitemid 37281375)
39. A. Carriere, M.C. Carmona, and Y. Fernandez Mitochondrial reactive oxygen species control the transcription factor CHOP-10/GADD153 and adipocyte differentiation: a mechanism for hypoxia-dependent effect The Journal of Biological Chemistry 279 2004 40462 40469 (Pubitemid 39287636)
40. A.D. Badley, T. Roumier, and J.J. Lum Mitochondrion-mediated apoptosis in HIV-1 infection Trends in Pharmacological Sciences 24 2003 298 305 (Pubitemid 36725005)
41. F. Villarroya, P. Domingo, and M. Giralt Lipodystrophy associated with highly active anti-retroviral therapy for HIV infection: the adipocyte as a target of anti-retroviral-induced mitochondrial toxicity Trends in Pharmacological Sciences 26 2005 88 93 (Pubitemid 40170171)
42. M. Giralt, P. Domingo, and J.P. Guallar HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV- 1/HAART-associated lipodystrophy Antiviral Therapy 11 2006 729 740 (Pubitemid 44497168)
43. B. Lindegaard, A.B. Hansen, and H. Pilegaard Adipose tissue expression of IL-18 and HIV-associated lipodystrophy AIDS 18 2004 1956 1958 (Pubitemid 39313213)
44. V. Jan, P. Cervera, and M. Maachi Altered fat differentiation and adipocytokine expression are inter-related and linked to morphological changes and insulin resistance in HIV-1-infected lipodystrophic patients Antiviral Therapy 9 2004 555 564 (Pubitemid 39150213)
45. J.P. Bastard, M. Caron, and H. Vidal Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance Lancet 359 2002 1026 1031 (Pubitemid 34286541)
46. K. Sevastianova, J. Sutinen, and K. Kannisto Adipose tissue inflammation and liver fat in patients with highly active antiretroviral therapy-associated lipodystrophy American Journal of Physiology. Endocrinology and Metabolism 295 2008 E85 E91
47. J.P. Guallar, J.M. Gallego-Escuredo, and J.C. Domingo Differential gene expression indicates that 'buffalo hump' is a distinct adipose tissue disturbance in HIV-1-associated lipodystrophy AIDS 22 2008 575 584 (Pubitemid 351640590)
48. P. Domingo, J.P. Guallar, and J.M. Gallego-Escuredo Genome-wide transcriptomic análisis reveals distinct patterns of altered gene expression in subcutaneous adipose tissue associated with HIV-1 infection, antiretroviral treatment and lipodystrophy Antiviral Therapy 13 Suppl. 4 2008 A25
49. S. Gasic, B. Tian, and A. Green Tumor necrosis factor alpha stimulates lipolysis in adipocytes by decreasing Gi protein concentrations The Journal of Biological Chemistry 274 1999 6770 6775 (Pubitemid 29111100)
50. M.J. Kim, P. Leclercq, and E. Lanoy A 6-month interruption of antiretroviral therapy improves adipose tissue function in HIV-infected patients: the ANRS EP29 Lipostop Study Antiviral Therapy 12 2007 1273 1283
51. J.P. Guallar, P. Cano-Soldado, and I. Aymerich Altered expression of nucleoside transporter genes (SLC28 and SLC29) in adipose tissue from HIV-1-infected patients Antiviral Therapy 12 2007 853 863 (Pubitemid 47492555)
52. M.V. Stankov, R.E. Schmidt, and G.M. Behrens Combined effect of C-reactive protein and stavudine on adipogenesis Antiviral Therapy 14 2009 819 829
53. A. Rodriguez, V. Catalan, and J. Gomez-Ambrosi Visceral and subcutaneous adiposity: are both potential therapeutic targets for tackling the metabolic syndrome? Current Pharmaceutical Design 13 2007 2169 2175 (Pubitemid 47074048)
54. M. Lafontan, and M. Berlan Do regional differences in adipocyte biology provide new pathophysiological insights? Trends in Pharmacological Sciences 24 2003 276 283 (Pubitemid 36725002)
55. J. Kovsan, A. Osnis, and A. Maissel Depot-specific adipocyte cell lines reveal differential drug-induced responses of white adipocytes - relevance for partial lipodystrophy American Journal of Physiology. Endocrinology and Metabolism 296 2009 E315 E322
56. C. Deveaud, B. Beauvoit, and S. Hagry Site specific alterations of adipose tissue mitochondria in 3′-azido-3′-deoxythymidine (AZT)-treated rats: an early stage in lipodystrophy? Biochemical Pharmacology 70 2005 90 101 (Pubitemid 40803449)
57. J. Villarroya, J.M. Gallego-Escuredo, and J.C. Domingo Differential alterations of gene expression in visceral versus subcutaneous adipose tissue from HIV-1-infected, HAART-treated patients with lipodystrophy: a pilot study Antiviral Therapy 13 Suppl. 4 2010 A15
58. J.C. Lo, K. Mulligan, and V.W. Tai "Buffalo hump" in men with HIV-1 infection Lancet 351 1998 867 870 (Pubitemid 28121175)
59. P.W. Mallon, H. Wand, and M. Law Buffalo hump seen in HIV-associated lipodystrophy is associated with hyperinsulinemia but not dyslipidemia Journal of Acquired Immune Deficiency Syndromes 38 2005 156 162 (Pubitemid 40189322)
60. W.J. Fessel, S.B. Follansbee, and B. Barker Ultrastructural findings consistent with brown adipocytes in buffalo humps of HIV-positive patients with fat redistribution syndrome Antiviral Therapy 5 2000 25
61. F. Villarroya, P. Domingo, and M. Giralt The importance of brown adipose tissue The New England Journal of Medicine 361 2009 417 421
62. B. Cannon, and J. Nedergaard Brown adipose tissue: function and physiological significance Physiological Reviews 84 2004 277 359 (Pubitemid 38054374)
63. M.L. Rodriguez de la Concepcion, P. Yubero, and J.C. Domingo Reverse transcriptase inhibitors alter uncoupling protein-1 and mitochondrial biogenesis in brown adipocytes Antiviral Therapy 10 2005 515 526 (Pubitemid 41059198)
64. N. Clumeck, N. Dedes, A. Pozniak, and EACS Executive Committee European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults in Europe 2009 Available at http://www.europeanaidsclinicalsociety.org/guidelinespdf/EACS- EuroGuidelines2009FullVersion.pdf [accessed 1.09 10]
65. Panel de expertos de Gesida y Plan Nacional sobre el Sida. Documento de consenso de Gesida/Plan Nacional sobre el SIDA respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana: actualización enero 2010 Enfermedades infecciosas y microbiología clínica 28 6 2010 362
66. McComsey G, Kitch D, Daar E. et al. Bone and limb fat outcomes of ACTG A5224s, a substudy of ACTG A5202: a prospective, randomized, partially blinded phase III trial of ABC/3TC or TDF/FTC with EFV or ATV/r for initial treatment of HIV-1 infection. 17th Conference on Retrovirus and Opportunistic Infections Feb 16-19, 2010 San Francisco 2010; Abstract 106LB.
67. Mocroft A, Reiss P, Gasiorowski P. et al. Serious fatal and non-fatal non-AIDS-defining illnesses in Europe. 16th Conference on Retroviruses and Opportunistic Infections Montreal, Canada 2009; Abstract 707.
68. K.A. Lichtenstein Redefining lipodystrophy syndrome: risks and impact on clinical decision making Journal of Acquired Immune Deficiency Syndromes 39 2005 395 400 (Pubitemid 41003782)
69. V. Asensi, C. Rego, and A.H. Montes IL-1beta (+3954C/T) polymorphism could protect human immunodeficiency virus (HIV)-infected patients on highly active antiretroviral treatment (HAART) against lipodystrophic syndrome Genetics in Medicine 10 2008 215 223 (Pubitemid 351416819)
70. K. Ranade, W.J. Geese, and M. Noor Genetic analysis implicates resistin in HIV lipodystrophy AIDS 22 2008 1561 1568
71. P.B. Zanone, A. Riva, and M. Nasi Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy AIDS 22 2008 1769 1778
72. P. Leyes, E. Martinez, and M.T. Forga Use of diet, nutritional supplements and exercise in HIV-infected patients receiving combination antiretroviral therapies: a systematic review Antiviral Therapy 13 2008 149 159 (Pubitemid 351535367)
73. C. Hadigan Dietary habits and their association with metabolic abnormalities in human immunodeficiency virus-related lipodystrophy Clinical Infectious Diseases 37 Suppl. 2 2003 S101 S104
74. M.M. Foisy, E.M. Yakiwchuk, and I. Chiu Adrenal suppression and Cushing's syndrome secondary to an interaction between ritonavir and fluticasone: a review of the literature HIV Medicine 9 2008 389 396 (Pubitemid 352015642)
75. Study of fat redistribution and metabolic change in HIV infection (FRAM). Fat distribution in women with HIV infection Journal of Acquired Immune Deficiency Syndromes 42 2006 562 571
76. C. Grunfeld, M. Saag, and J. Cofrancesco Jr. Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy AIDS 24 2010 1717 1726
77. F.M. Malita, A.D. Karelis, and E. Toma Effects of different types of exercise on body composition and fat distribution in HIV-infected patients: a brief review Canadian Journal of Applied Physiology 30 2005 233 245 (Pubitemid 40627545)
78. H. Drechsler, and W.G. Powderly Switching effective antiretroviral therapy: a review Clinical Infectious Diseases 35 2002 1219 1230 (Pubitemid 35305870)
79. B.R. Hansen, S.B. Haugaard, and J. Iversen Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: a review Scandinavian Journal of Infectious Diseases 36 2004 244 253 (Pubitemid 38714175)
80. M. John, E.J. McKinnon, and I.R. James Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients Journal of Acquired Immune Deficiency Syndromes 33 2003 29 33 (Pubitemid 36547238)
81. A. Milinkovic, E. Martinez, and S. Lopez The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients Antiviral Therapy 12 2007 407 415 (Pubitemid 46787986)
82. E. Martinez, F. Visnegarwala, and B. Grund The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters AIDS 24 2010 353 363
83. E. Martinez, A. Milinkovic, and F. Garcia Greater limb fat increase with intermittent (relative to continuous) thymidine-sparing antiretroviral therapy in HIV-infected patients with lipoatrophy Antiviral Therapy 13 2008 A9
84. A. Carr, C. Workman, and D.E. Smith Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial JAMA: the Journal of the American Medical Association 288 2002 207 215 (Pubitemid 34755281)
85. P. Tebas, J. Zhang, and K. Yarasheski Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s) Journal of Acquired Immune Deficiency Syndromes 45 2007 193 200 (Pubitemid 46869812)
86. M. Fisher, G.J. Moyle, and M. Shahmanesh A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals Journal of Acquired Immune Deficiency Syndromes 51 2009 562 568
87. A. Martin, D.E. Smith, and A. Carr Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study AIDS 18 2004 1029 1036 (Pubitemid 38591194)
88. H. Yki-Jarvinen Thiazolidinediones The New England Journal of Medicine 351 2004 1106 1118
89. J.M. Raboud, C. Diong, and A. Carr A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy HIV Clinical Trials 11 2010 39 50
90. S.H. Sheth, and R.J. Larson The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials BMC Infectious Diseases 10 2010 183
91. P.W. Mallon, R. Sedwell, and G. Rogers Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction The Journal of Infectious Diseases 198 2008 1794 1803
92. Slama L, Lavoy E, Valentin MA. et al. Effect of pioglitazone on HIV-1 related lipoatrophy: a randomized double-blind placebo-controlled trial (ANRS 113) with 130 patients. 13th Conference on Retrovirus and Opportunistic Infection, Denver, February 5-8; 2006 Abstract 151LB.
93. M. Tungsiripat, D.E. Bejjani, and N. Rizk Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimens AIDS 24 2010 1291 1298
94. S. Kaul, A.F. Bolger, and D. Herrington Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart association and American College of Cardiology Foundation Circulation 121 2010 1868 1877
95. Guaraldi G, Fontdevilla J, Christensern LH. et al. Surgical correction of HIV-associated facial lipoatrophy. AIDS (in press).
96. J. Fontdevila, J.M. Serra-Renom, and M. Raigosa Assessing the long-term viability of facial fat grafts: an objective measure using computed tomography Aesthetic Surgery Journal 28 2008 380 386 (Pubitemid 352020652)
97. G. Moyle, M. Moutschen, and E. Martinez Epidemiology, assessment, and management of excess abdominal fat in persons with HIV infection AIDS Reviews 12 2010 3 14
98. S. Bhasin, R.A. Parker, and F. Sattler Effects of testosterone supplementation on whole body and regional fat mass and distribution in human immunodeficiency virus-infected men with abdominal obesity The Journal of Clinical Endocrinology and Metabolism 92 2007 1049 1057 (Pubitemid 46465682)
99. C. Hadigan, C. Corcoran, and N. Basgoz Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial JAMA: the Journal of the American Medical Association 284 2000 472 477 (Pubitemid 30484481)
100. R. Kohli, A. Shevitz, and S. Gorbach A randomized placebo-controlled trial of metformin for the treatment of HIV lipodystrophy HIV Medicine 8 2007 420 426 (Pubitemid 47335264)
101. E. Martinez, P. Domingo, and E. Ribera Effects of metformin or gemfibrozil on the lipodystrophy of HIV-infected patients receiving protease inhibitors Antiviral Therapy 8 2003 403 410 (Pubitemid 37351558)
102. K. Mulligan, Y. Yang, and D.A. Wininger Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio AIDS 21 2007 47 57 (Pubitemid 44912536)
103. Y.E. Snel, R.J. Brummer, and M.E. Doerga Adipose tissue assessed by magnetic resonance imaging in growth hormone-deficient adults: the effect of growth hormone replacement and a comparison with control subjects American Journal of Clinical Nutrition 61 1995 1290 1294
104. P. Rietschel, C. Hadigan, and C. Corcoran Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy The Journal of Clinical Endocrinology and Metabolism 86 2001 504 510 (Pubitemid 32207451)
105. J. Falutz, S. Allas, and K. Blot Metabolic effects of a growth hormone-releasing factor in patients with HIV The New England Journal of Medicine 357 2007 2359 2370 (Pubitemid 350223390)
106. J. Falutz, D. Potvin, and J.C. Mamputu Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension Journal of Acquired Immune Deficiency Syndromes 53 2010 311 322
107. R.M. Johnson Reduction mammoplasty in an HIV-positive woman AIDS Patient Care STDs 19 2005 353 355 (Pubitemid 40962009)
108. C.S. Hultman, L.E. McPhail, and J.H. Donaldson Surgical management of HIV-associated lipodystrophy: role of ultrasonic-assisted liposuction and suction-assisted lipectomy in the treatment of lipohypertrophy Annals of Plastic Surgery 58 2007 255 263 (Pubitemid 46667869)
109. L. Nelson, and K.J. Stewart Plastic surgical options for HIV-associated lipodystrophy Journal of Plastic, Reconstructive & Aesthetic Surgery 61 2008 359 365 (Pubitemid 351389382)